The Preclinical Evaluation of a Second-Generation Antivenom for Treating Snake Envenoming in India.

ABSTRACT: Snake envenoming afflicts the Indian subcontinent with the highest rates of mortality (47,000) and morbidity globally. The only effective treatment for snakebites is the administration of antivenom, which is produced by the hyperimmunisation of equines. Commercial Indian antivenoms, however, have been shown to exhibit a poor preclinical performance in neutralising venom, as a result of inter- and intrapopulation snake venom variation. Additionally, their poor dose effectiveness necessitates the administration of larger volumes of antivenom for treatment, leading to several harmful side effects in snakebite victims, including serum sickness and fatal anaphylaxis. In this study, we employed chromatographic purification to enhance the dose efficacy of commercial Indian antivenoms. The efficac

SUBMITTER: Attarde S 

PROVIDER: S-EPMC8950585 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature